Search results for "CARE"

showing 10 items of 9420 documents

Cytomegalovirus vector expressing RAE-1γ induces enhanced anti-tumor capacity of murine CD8+ T cells

2017

Designing of CD8 T cell vaccines which would provide protection against tumors is still considered a great challenge in immunotherapy. Here we show a robust potential of a cytomegalovirus (CMV) vector expressing the NKG2D ligand RAE-1γ as CD8 T cell-based vaccine against malignant tumors. Immunization with the CMV vector expressing RAE-1γ delayed tumor growth or even provided complete protection against tumor challenge in both prophylactic and therapeutic settings. Moreover, a potent tumor control in mice vaccinated with this vector can be further enhanced by blocking the immune checkpoints TIGIT and PD-1. Expression of RAE-1γ by the CMV vector potentiated expansion of KLRG1+ CD8 T cells wi…

0301 basic medicineTumor vaccine [RAE-1γ]medicine.medical_treatmentT cellImmunologyGenetic VectorsProgrammed Cell Death 1 ReceptorMelanoma ExperimentalCytomegalovirusEpitopes T-LymphocyteBiologyCD8-Positive T-LymphocytesCancer VaccinesArticleCMV vectorNKG2DImmunomodulation03 medical and health sciencesMiceImmune systemTIGITKLRG1+ CD8+ T cellsNeoplasmsmedicineImmunology and AllergyCytotoxic T cellAnimalsHumansRAE-1γ : Tumor vaccineLectins C-TypeReceptors ImmunologicαTIGIT ; CMV vector ; KLRG1+ CD8+ T cells ; NKG2D ; RAE-1γ : Tumor vaccineBIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.Membrane ProteinsImmunotherapyNKG2DVirology3. Good healthKiller Cells NaturalDisease Models Animal030104 developmental biologymedicine.anatomical_structureImmunizationAnimals NewbornFemaleαTIGITImmunotherapyBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.CD8
researchProduct

Global surveillance of trends in cancer survival 2000-14 (concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18…

2018

Eser, Sultan (Balikesir Author)

0301 basic medicineUniversal Health Coveragepopulation-based registriesRelative SurvivalSettore MED/42 - Igiene Generale E ApplicataCancer -- TreatmentHumans; Neoplasms; Population Surveillance; Registries; Survival Rate; Medicine (all)0302 clinical medicineNeoplasmsRegistriescancer survivaleducation.field_of_studyRelative survivalMedicine (all)EPICENEGeneral Medicine3. Good healthSurvival Ratetrend030220 oncology & carcinogenesisPopulation SurveillancePublic-Healthcancer surveillanceLiver cancersurvival ; cancer registry ; CONCORD-3CureChildhood-Cancermedicine.medical_specialtypopulation-based cancer registriesWomens CancersPopulationMedicine (all)cancer survival population-based cancer registriesSocio-culturaleUnited-StatessurvivalArticle03 medical and health sciencesBreast cancerCancer epidemiologymedicineHumansNordic-CountriesCancer -- MortalityeducationSurvival rateCancer preventionAlternative Approachbusiness.industryPublic healthCancerCancer -- Patients -- Long-term caremedicine.disease030104 developmental biologyHigh-Income Countries[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessDemography
researchProduct

Thrombo-Inflammation in Cardiovascular Disease

2020

AbstractThrombo-inflammation describes the complex interplay between blood coagulation and inflammation that plays a critical role in cardiovascular diseases. The third Maastricht Consensus Conference on Thrombosis assembled basic, translational, and clinical scientists to discuss the origin and potential consequences of thrombo-inflammation in the etiology, diagnostics, and management of patients with cardiovascular disease, including myocardial infarction, stroke, and peripheral artery disease. This article presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following topics: (1) challenges of the endothelial cell barrier; (2) circulating …

0301 basic medicineVENOUS THROMBOSISmedicine.medical_specialtypulmonary embolismNeutrophilsIschemiaISCHEMIA-REPERFUSION INJURYDisease030204 cardiovascular system & hematologyCATHETER-DIRECTED THROMBOLYSIS03 medical and health sciences0302 clinical medicinePERIPHERAL ARTERY-DISEASEMedicineAnimalsHumansPlateletMyocardial infarctionDEEP-VEIN THROMBOSIScoagulationIntensive care medicineStrokeBlood CoagulationExpert Testimonythrombosisbusiness.industryACUTE CORONARY SYNDROMESNEUTROPHIL EXTRACELLULAR TRAPSHematologyNeutrophil extracellular trapsVenous ThromboembolismACTIVATABLE FIBRINOLYSIS INHIBITORmedicine.diseaseAtherosclerosisThrombosisstrokeImmunity Innate3. Good healthVenous thrombosis030104 developmental biologymyocardial infarctionTISSUE FACTORCardiovascular DiseasesinflammationplateletsEndothelium VascularbusinessSUBCLINICAL LEAFLET THROMBOSISThrombosis and Haemostasis
researchProduct

Vitamin D and Cardiovascular Health

2021

The principal source of vitamin D in humans is its biosynthesis in the skin through a chemical reaction dependent on sun exposure. In lesser amounts, the vitamin can be obtained from the diet, mostly from fatty fish, fish liver oil and mushrooms. Individuals with vitamin D deficiency, defined as a serum level of 25 hydroxyvitamin D < 20 ng/dl, should be supplemented. Vitamin D deficiency is a prevalent global problem caused mainly by low exposure to sunlight. The main role of 1,25 dihydroxyvitamin D is the maintenance of calcium and phosphorus homeostasis. However, vitamin D receptors are found in most human cells and tissues, indicating many extra-skeletal effects of the vitamin, particula…

0301 basic medicineVitaminmedicine.medical_specialtyVitamina DEnfermedad cardiovascularchemistry.chemical_element030209 endocrinology & metabolismCalciumCritical Care and Intensive Care Medicinemedicine.disease_causevitamin D deficiencyNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemInternal medicineHipertensiónmedicineVitamin D and neurologyHumansSupplementsVitamin D030109 nutrition & dieteticsNutrition and DieteticsEnfermedad coronariabusiness.industryEndothelial functionVitamin D Deficiencymedicine.diseaseCardiovascular diseaseCoronary heart diseaseEndocrinologyDietéticachemistryCardiovascular DiseasesNutriciónHypertensionNarrative ReviewbusinessHomeostasisOxidative stress
researchProduct

Why Are New Drugs Expensive and How Can They Stay Affordable?

2019

Increasing life expectancy leading to a higher median age causes an increasing need for healthcare resources, which is aggravated by an increasing prevalence of preventable diseases such as type 2 diabetes. This includes increasing expenditures for medicines, although these increases when expressed as a share of overall societal wealth are more moderate than often claimed. An increasing use of generic medicines (currently about 90% of all prescriptions) means that costs for discovery and development of innovative drugs must be recovered on a shrinking percentage of prescriptions. However, the key challenge to affordable drugs is exponentially increasing costs to bring a new medicine to the …

0301 basic medicinebusiness.industryMedizinmedicine.diseaseA share03 medical and health sciences030104 developmental biology0302 clinical medicineDrug developmentHealth careDevelopment economicsmedicineLife expectancyAttrition030212 general & internal medicineBusinessMedical prescriptionDrug pricing
researchProduct

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

2020

AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…

0301 basic medicinecoronavirusAnti-Inflammatory AgentsReview Article030204 cardiovascular system & hematologymedicine.disease_causelaw.inventioncovid190302 clinical medicineRandomized controlled triallawAntithromboticPandemicViralanticoagulationCoronavirusGlycosaminoglycansAnimals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia Viral; Thrombosiscoronavirus 2immunomodulatorHematologyHeparinThrombosisantithrombinCoronavirus Infectionsmedicine.drugmedicine.medical_specialtyPneumonia Viralcoronavirus disease 2019 thrombosis inflammation fibrinolytic therapy anticoagulation immunomodulator antithrombin thrombomodulinAntiviral Agents03 medical and health sciencescoronavirus disease 2019BetacoronavirusFibrinolytic AgentsmedicineAnimalsHumansthrombosis COVID-19 coronavirusDosingIntensive care medicinePandemicsthrombosisInflammationHemostasisbusiness.industrySARS-CoV-2AnticoagulantsCOVID-19ThrombosisPneumoniathrombomodulinmedicine.diseaseReview articleCOVID-19 Drug Treatment030104 developmental biologyinflammationfibrinolytic therapybusinessPlatelet Aggregation InhibitorsThrombosis and haemostasis
researchProduct

Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH sur…

2017

Background Scant information is available about how transplant centers are managing their use of quantitative molecular testing (QNAT) assays for active cytomegalovirus (CMV) infection monitoring in solid organ transplant (SOT) recipients. The current study was aimed at gathering information on current practices in the management of CMV infection across European centers in the era of molecular testing assays. Methods A questionnaire-based cross-sectional survey study was conducted by the European Study Group of Infections in Immunocompromised Hosts (ESGICH) of the Society of Clinical Microbiology and Infectious Diseases (ESCMID). The invitation and a weekly reminder with a personal link to …

0301 basic medicinecytomegalovirus; solid organ transplantation; survey.cytomegalovirus ; solid organ transplantation ; surveyCross-sectional studyCytomegalovirusTransplantsPractice Patterns030230 surgeryOrgan transplantationlaw.invention0302 clinical medicinePostoperative Complicationslaw03.02. Klinikai orvostanViralPractice Patterns Physicians'solid organ transplantationPolymerase chain reactionViral LoadEuropeInfectious DiseasesCytomegalovirus InfectionsPractice Guidelines as Topiccytomegalovirus; solid organ transplantation; survey; Antibiotic Prophylaxis; Antiviral Agents; Cross-Sectional Studies; Cytomegalovirus; Cytomegalovirus Infections; DNA Viral; Europe; Guideline Adherence; Health Care Surveys; Humans; Immunocompromised Host; Immunosuppression; Organ Transplantation; Postoperative Complications; Practice Guidelines as Topic; Practice Patterns Physicians'; Real-Time Polymerase Chain Reaction; Transplant Recipients; Transplants; Viral LoadGuideline Adherencecytomegalovirus; solid organ transplantation; survey; Antibiotic Prophylaxis; Antiviral Agents; Cross-Sectional Studies; Cytomegalovirus; Cytomegalovirus Infections; DNA Viral; Europe; Guideline Adherence; Health Care Surveys; Humans; Immunocompromised Host; Immunosuppression; Organ Transplantation; Postoperative Complications; Practice Guidelines as Topic; Practice Patterns Physicians'; Real-Time Polymerase Chain Reaction; Transplant Recipients; Transplants; Viral Load; Transplantation; Infectious Diseasesmedicine.medical_specialty030106 microbiologyCongenital cytomegalovirus infectionReal-Time Polymerase Chain ReactionAntiviral Agents03 medical and health sciencesImmunocompromised HostmedicineHumanssurveyIntensive care medicineImmunosuppression TherapyTransplantationPhysicians'business.industryDNAOrgan TransplantationAntibiotic Prophylaxismedicine.diseaseMolecular diagnosticsTransplant RecipientsCytomegalovirus infectionTransplantationcytomegalovirus; solid organ transplantation; survey; Transplantation; Infectious DiseasesCross-Sectional StudiesCytomegalovirus; Solid organ transplantation; Survey; Transplantation; Infectious DiseasesHealth Care SurveysDNA ViralImmunologySolid organ transplantationbusinessImmunosuppression
researchProduct

Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort

2020

Abstract Objectives To describe: (i) factors associated with rapid and delayed ART initiation; (ii) rates of 12 week virological response; and (iii) virologically controlled retention in care by 1 year from ART initiation according to timing of start in a real-life setting. Methods All individuals in the Icona cohort diagnosed with HIV in 2016–17 who initiated ART were grouped according to the time between HIV diagnosis and ART initiation: Group 1, ≤7 days; Group 2, 8–14 days; Group 3, 15–30 days; Group 4, 31–120 days; and Group 5, &amp;gt;120 days. Multivariable logistic regression models were used to identify factors associated with: (i) the probability of rapid (Group 1) and very delayed…

0301 basic medicinediagnosishivcommunicable diseasesHIV InfectionsLogistic regressionVirological responseCohort Studies0302 clinical medicineRetention in CareMedicinePharmacology (medical)HIV Infection030212 general & internal medicineProspective cohort studycd4 count determination proceduredrugsuppressionViral LoadCD4 Lymphocyte Count; Cohort Studies; Humans; Italy; Viral Load; Anti-HIV Agents; HIV Infections; Retention in CarevirologyInfectious DiseasesItalyblood hiv rnaCohorthiv cd4 count determination procedure communicable diseases incomeitaly diagnosis virology blood hiv rna retention in careincomeitalyViral loadHIV ARTCohort studyHumanMicrobiology (medical)medicine.medical_specialtyAnti-HIV Agentsantiretroviral therapySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesHIV viral loadInternal medicineHumansHIV CD4 ARTPharmacologybusiness.industrydouble blindAnti-HIV AgentHIV viral load antiretroviral therapy double blind initiation suppression infectionRetention in care030112 virologyinfectioninitiationCD4 Lymphocyte CountObservational studyCohort Studiebusiness
researchProduct

Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors

2020

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors are so called “incretin-based therapies” (IBTs) that represent innovative therapeutic approaches and are commonly used in clinical practice for the treatment of type 2 diabetes mellitus (T2DM). The cardiovascular outcome trials (CVOTs) have provided useful information that has helped to shape changes in clinical practice guidelines for the management of T2DM. At the same time, the mechanisms that may explain the nonglycemic and cardiovascular (CV) benefits of these medications are still being explored. A summary of the main findings from CVOTs performed to-date with particular emphasis on vari…

0301 basic medicineendocrine systemmedicine.medical_specialtyDipeptidyl Peptidase 4Endocrinology Diabetes and MetabolismIncretin030209 endocrinology & metabolismClass effectBody weightCardiovascular SystemIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineType 2 diabetes mellitusmedicineAnimalsHumansIntensive care medicineGlucagon-like peptide 1 receptorDipeptidyl-Peptidase IV Inhibitorsbusiness.industryDPP-4 Inhibitorsdigestive oral and skin physiologyType 2 Diabetes MellitusCardiovascular riskDPP4- inhibitorClinical Practice030104 developmental biologyCardiovascular DiseasesGlucagon-like peptide 1 receptor agonistbusinessCardiovascular outcomesMetabolism
researchProduct

Biomarkers for the Noninvasive Diagnosis of Endometriosis: State of the Art and Future Perspectives

2020

Background: Early and accurate diagnosis of endometriosis is crucial for the management of this benign, yet debilitating pathology. Despite the advances of modern medicine, there is no common ground regarding the pathophysiology of this disease as it continues to affect the quality of life of millions of women of reproductive age. The lack of specific symptoms often determines a belated diagnosis. The gold standard remains invasive, surgery followed by a histopathological exam. A biomarker or a panel of biomarkers is easy to measure, usually noninvasive, and could benefit the clinician in both diagnosing and monitoring the treatment response. Several studies have advanced the idea of biomar…

0301 basic medicineendometriosisProteomicsEndometriosisDiseaseReviewlcsh:ChemistryangiogenesisEndometrium0302 clinical medicinelcsh:QH301-705.5SpectroscopyOligonucleotide Array Sequence Analysis030219 obstetrics & reproductive medicineNeovascularization PathologicGeneral MedicineGenomicsComputer Science ApplicationsBiomarker (medicine)biomarkerFemalemedicine.medical_specialtyTreatment responseModern medicineCatalysisInorganic Chemistry03 medical and health sciencesmedicineHumansMetabolomicsurinary biomarkersPhysical and Theoretical ChemistryIntensive care medicineMolecular BiologyNoninvasive biomarkersAutoantibodiesInflammationbusiness.industryOrganic ChemistryGold standard (test)medicine.diseaseUrinary biomarkerscytokinesMicroRNAsOxidative Stress030104 developmental biologylcsh:Biology (General)lcsh:QD1-999businessPeptidesBiomarkersInternational Journal of Molecular Sciences
researchProduct